Illumina, Inc.

Matched from indexed company URL: ILLUMINA, INC.

FDA Registration(s)#

Registration, FEI, Name table
RegistrationFEINameStatusInitial importerExpiration yearAddress
30032189063003218906Illumina, Inc.1N2026-01-015200 Illumina Way San Diego CA US 92122
30062963463005095756Illumina, Inc. Hayward1N2026-01-0125841 Industrial Blvd Hayward CA US 94545
30219023553021902355ILLUMINANT SURGICAL, INC.1N2026-01-012440 S Sepulveda Blvd Ste 125 Los Angeles CA US 90064

GUDID Contact Samples#

Sampled from matched GUDID device records for this company; this is not an exhaustive company contact directory.

Source GUDID, Product, Phone table
Source GUDIDProductPhoneEmail
00816270020217TruSight™ Oncology Comprehensive - The TruSight Oncology Comprehensive assay is an enrichment-based targeted next generation sequencing (NGS) in-vitro diagnostic test comprised of library preparation and enrichment reagents to enable DNA and/or RNA sequencing from Formalin-Fixed, Paraffin-Embedded (FFPE) tissue from solid tumors encompassing multiple cancer types.800-809-4566techsupport@illumina.com
00816270020262Local Run Manager CF Clinical Sequencing Analysis Module - The Local Run Manager CF Clinical Sequencing analysis module is for use with Illumina MiSeqDx Cystic Fibrosis Clinical Sequencing Assay. The assay detects mutations in the protein coding regions and intron/exon boundaries of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, including two large deletions and two-deep intronic mutations. The analysis module performs secondary analysis and report generation from sequencing runs that use the MiSeqDx Cystic Fibrosis Clinical Sequencing Assay.800-809-4566techsupport@illumina.com
00816270020286Local Run Manager CF 139 Variant Analysis Module - The Local Run Manager CF 139 Variant analysis module is for use with Illumina MiSeqDx Cystic Fibrosis 139-Variant Assay. The assay detects 139 clinically relevant cystic fibrosis disease-causing mutations and variants of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in genomic DNA isolated from human peripheral whole blood specimens. The analysis module performs secondary analysis and report generation from sequencing runs that use the MiSeqDx Cystic Fibrosis 139-Variant Assay.800-809-4566techsupport@illumina.com

Registered Device Listings#

Registration key, Listing key, Premarket submission table
Registration keyListing keyPremarket submissionDeviceProduct codeDecision date
1083631728329084P230011TruSight Oncology ComprehensivePQP2024-08-21
1083631875213119P160038Praxis Extended RAS PanelPQP2017-06-29
1083631629919860K132750ILLUMINA MISEQDX CYSTIC FIBROSIS CLINICAL SEQUENCING ASSAYPFS2013-11-19
1083631072070739K124006ILLUMINA MISEQDX CYSTIC FIBROSIS 139-VARIANT ASSAYPFR2013-11-19
1083631906819655DEN130042MISEQDX UNIVERSAL KIT 1.0PFT2013-11-19
1083631618426248DEN130011ILLUMINA MISEQDX PLATFORMPFF2013-11-19
1666431618426248DEN130011ILLUMINA MISEQDX PLATFORMPFF2013-11-19
1083631065135491
1083631519684938
3036501609876598
1083631723639894
1666431723639894

Product Codes Associated With Registrations#

Product code, Registration listing records, Latest decision table
Product codeRegistration listing recordsLatest decision
PFF22013-11-19
PFR22013-11-19
PQP12017-06-29
PFS12013-11-19
PFT12013-11-19

PMA#

PMN#

GUDID#